All News
The Need for Comparative Treatment Trials in Psoriatic Arthritis
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Read Article
#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout
⭐️Effectively brought down serum uric acid <5, dose-dependent
⭐️10% pts gout flare with urate lowering
@Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ
Links:
Eric Dein ericdeinmd ( View Tweet)
Minority (African American and Hispanic) #SLE patients have worse #COVID19 outcomes – double whammy! Data from the @rheum_covid #ACR21 @rheumnow #abst1933
Bella Mehta bella_mehta ( View Tweet)
#ACR21 L07 - Rx for IBM?!
⭐️Depletion of KLRG1+ T cells - trial of ABC008
⭐️Presented data from 3 patients in 1st human studies
▶️single SC 0.1 mg/kg dose depletes CD8+KLRG1+ cells wo safety concerns
@Rheumnow https://t.co/1J8PrOqbWh
Links:
Eric Dein ericdeinmd ( View Tweet)
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation
Now there hope might be on the horizon
Exciting to see the science & a feasible target
#ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew drdavidliew ( View Tweet)
Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80
Dr. Antoni Chan synovialjoints ( View Tweet)
#SLE patients with limited health literacy affects vulnerable black patients in multiple domains – worse disease activity/damage, physician/patient communication, worse patient centered care, and patient activation @mithurheum #ACR21 @rheumnow #ACRBest abst#L08
Bella Mehta bella_mehta ( View Tweet)
To be clear, for IBM: resignation 'not that long ago' = yesterday. Early days I know, but nothing like a plausible, feasible target to bring hope
@UpToDate screenshot
exciting times at #ACR21 @RheumNow https://t.co/WAEUtQagym
David Liew drdavidliew ( View Tweet)
#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD
⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size
▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT
@Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja
Links:
Eric Dein ericdeinmd ( View Tweet)
#Sleep disturbance is common in #RA but does it correlate with disease activity?
Results from >100 RA pts suggest yes.
Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity.
Abs#1666 #ACR21 @RheumNow
https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Predicting RA, and Treatment of Subclinical Arthritis
Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis.
https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU
Links:
Dr. John Cush RheumNow ( View Tweet)
My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Watch back our recap of the best from Day 2 of #ACR21 in the @RheumNow daily panel. With @AurelieRheumo @RheumNow @Yuz6Yusof @bella_mehta @_Castillo_Pedro https://t.co/ORTbV61c2C
Richard Conway RichardPAConway ( View Tweet)
Watch my video of #ACR21 Abstract 1456, a double blind RCT of CBD for hand OA and PsA @RheumNow https://t.co/p0IiYzYe2m
Richard Conway RichardPAConway ( View Tweet)
Watch my video discussion of #ACR21 abstract 564 from @KronzerMD @jeffsparks on the association of upper airways disease with incident RA. https://t.co/Nkg9Yl9yYT @RheumNow
Richard Conway RichardPAConway ( View Tweet)
This case is from the hypereosinophilic syndrome talk. This was NOT EGPA! It was cancer. Be careful! #ACR21 @RheumNow https://t.co/UhdpeHBfOE
Richard Conway RichardPAConway ( View Tweet)
What is the effect of long-term #steroid use on major adverse #cardiovascular events (MACE)?
Find out in my video summary of abstract #1428 which was presented yesterday by @BethIWallace
Read here👉🏼https://t.co/fCM3m04ruS
Watch here👉🏼https://t.co/TLerQT7XnG
#ACR21 @RheumNow
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Avoid IFX drug holidays!
In this study 400+ pts
Dvlpmt of ADAs associated w/
▶️RA vs. SPA OR 2.1
▶️Smoking OR 1.8
▶️Drug holidays > 11 weeks OR 4.1
▶️High DA OR 1.5
while
◀️Concomitant IS drug OR 0.4
◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh
Aurelie Najm AurelieRheumo ( View Tweet)
My video comment on the cannabidiol (CBD) double-blinded RCT in hand OA/inactive PsA #ACR21 for @RheumNow
Great work by @Joner_MD et al
& kudos to funders @PsoriasisDK @Gigtforeningen @AalborgUH @aalborguni giving us data to answer a question often asked
https://t.co/e0mO0SriUu https://t.co/9DveN4jLls
Links:
David Liew drdavidliew ( View Tweet)